Related Experiment Video

Updated: Apr 17, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Global trends and research progress on immunotherapy for EGFR-mutant non-small cell lung cancer: a bibliometric

Qian Deng1,2, Na Li1,2

  • 1Department of Palliative Medicine, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China.

Journal of Thoracic Disease
|April 16, 2026
PubMed
Abstract

Insights

Global research on immunotherapy for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) shows rapid growth. Key research gaps include optimal sequencing, biomarkers, and resistance mechanisms, guiding future therapeutic strategies.

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Biology

Background:

  • Immunotherapy for EGFR-mutant NSCLC is a promising strategy.
  • Global research trends in this field are largely uncharacterized.
  • This study provides a bibliometric analysis of the field's evolution.

Purpose of the Study:

  • To conduct a comprehensive bibliometric analysis of EGFR-mutant NSCLC immunotherapy.
  • To characterize the evolution and current state of global research in this area.
  • To identify key research trends, collaborations, and influential entities.

Main Methods:

  • Bibliometric analysis of publications from 1995-2024.
  • Utilized Web of Science Core Collection, VOSviewer, CiteSpace, and R 'bibliometrix'.
  • Analyzed publication trends, citations, collaborations, and keywords.

Main Results:

  • 1,537 publications from 352 sources involving 12,131 authors were analyzed.
  • China led in publications; USA had the highest citation impact and collaboration.
  • Journal of Clinical Oncology was most influential; keyword analysis showed a shift towards immunotherapy and targeted therapies.

Conclusions:

  • EGFR-mutant NSCLC immunotherapy research is rapidly expanding.
  • Identified critical research gaps: optimal immunotherapy-EGFR-TKI sequencing, predictive biomarkers, and resistance mechanisms.
  • Findings guide future research to enhance therapeutic strategies in this evolving field.
Keywords:
Epidermal growth factor receptor-mutant non-small cell lung cancer (EGFR-mutant NSCLC)bibliometric analysisimmunotherapytreatment resistance

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.9K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K